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Abstract 
 Introduction: Pain is ubiquitarium in patients with irritable bowel 
syndrome (IBS) being associated  with diminished quality of life. 
Aim: comparing effectiveness of gabapentin high dose versus gabapentin 
half dose plus probiotics and dimeticone in mitigating the pelvic complaints 
in female patients with IBS .  
Methods: Open label random clinical study of 30 female patients, mean age= 
38,76±15,51 years, diagnosed with predominant constipation IBS, according 
to Rome III criteria, suffering from chronic pelvic complaints were enrolled 
after ruling out other causes of  pelvic symptoms. Intensity of  dyspareunia, 
cystalgia, urinary urge were scored according to Likert scale  from 0 = no 
symptoms to 6 = very severe. Patients were randomly devised in 2 groups, 
each of 15 patients. First group received gabapentinum in dose of 1200 
mg/day, the second group received  Gabapentin 600mg/day  associated  with 
probiotics (1 billion strains/ capsule Lactobacillus acidophilus 50% and 
Bifidobacterium bifidus 50% ),3 capsules/day plus dimeticone 80 mg, 3x2 
chewing  pills/day for 3 months. 
Results: First group had the following scoring : prior therapy dyspareunia 
=2,93±0,88. cystalgia =3±1,31, urinary urge =2,58±1,25; after therapy: 
dyspareunia= 2,20 ±0,77 (p=0,0022),cystalgia =2,2±0,86 (p=0,058),urinary 
urge =2,07±0,73 (p=0,26).Second group had the following scoring prior 
therapy: dyspareunia =3,13±1,06, cystalgia =2,73±1,16.urinary urge 
=1,87±1,13; after treatment: dyspareunia =1,6±0,63 (p<0,0001), cystalgia 
=1,40±0,50 (p=0,0003), urinary urge =0,66±0,61 (p=0,0011). 
Conclusions: Gabapentin in  high dose monotherapy was significantly 
efficient only for mitigating dyspareunia. Association with probiotics and 
dimeticone to gabapentin half doses resulted in an increased response and all 
the assessed complaints were significantly alleviated. 
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Introduction 
 Irritable bowel syndrome (IBS) is a functional  gastrointestinal(GI) 
disorder characterized by abdominal pain and altered bowel habits in the 
absence of specific and unique organic pathology, very often seen in modern 
and active women [Chang,2002]. 
 Pain, either abdominal or extra-abdominal, is ubiquitarium in patients 
with IBS and in many cases associated to diminished quality of life. It was 
traditionally explained, by  theories regarding pathophysiology, as a three 
part complex: altered GI motility, visceral hyperalgesia, and/or the abnormal 
processing of information by the central nervous system (CNS) 
[Camilleri,2002].   
 Altered GI motility includes distinct aberrations in small and large 
bowel motility and is probably associated to a generalized smooth muscle 
hyperresponsiveness. Visceral hyperalgesia characterizes IBS secondary to 
an enhanced perception of normal motility and rectosigmoid  balloon 
inflation produces more pain at lower volumes in patients than in controls.   
 Sensitization of the intestinal afferent nociceptive pathways, that 
synapse in the dorsal  horn of the spinal cord, could provide a unifying 
mechanism for abdominal pain. 
 It is by now well known that IBS is characterized not only by 
digestive issues but also by a lot of other complaints of great diversity, like: 
fibromyalgia , chronic fatigue syndrome, temporomandibular joint disorder 
and chronic pelvic pain(CPP).  The overlap of gynecologic conditions and 
IBS was noted in a study in which patients in a gynecologist's office had, in 
50% of cases, symptoms compatible with diagnosis of IBS.  CPP as a 
chronic condition, defined as pelvic pain of at least 6 months duration is 
estimated to affect approximately 15% of women and may be related, at least 
in part, to visceral hypersensitivity and is thought to involve multiple 
systems including the neurologic, musculoskeletal, and endocrine 
systems.[Gunter,2003].Despite a lot of research IBS remains a poorly 
understood condition and yet treatments of IBS are very heterogenous, none 
of them being quite satisfactory. 
 Much more dificult is the situation with IBS patients having 
concurrent conditions like CPP. A comprehensive treatment plan for women 
who have multiple concurrent conditions such as CPP and IBS has not yet 
been  developed and tested. 
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Objectives 
 The aim of this study was comparing efficiency of gabapentin alone, 
high dose versus gabapentin half dose plus probiotics and dimeticone in 
mitigating the pelvic complaints in IBS  patients, based on the observation 
that gabapentin was reported usefull in the treatment of fibromyalgia, 
condition very often associated with IBS, which has many common 
pathophysiologic pathways of pain. The rationale of including probiotics and 
dimeticone to therapy schedule was based on the fact that one of the major  
factor triggering the pelvic pain process in IBS is distension of the colon.  
 
Patients and methods 
 Study design: open label, random clinical study. 30 female patients, 
mean age= 38,76±15,51 years, diagnosed with IBS predominant constipation 
form, according to Rome III criteria [Spiller,2010] and  suffering from 
chronic pelvic complaints were enrolled in this study after ruling out other 
causes of  pelvic pain. An accurate disease history was taken, each patient 
being thoroughly examined. The intensities of  every symptom were scored 
by using  a 7-graded  Likert-like scale  from 0 = no symptoms to 6 = very 
severe symptom, according to Gastrointestinal Symptom Rating Scale 
(GSRS),   considering that this one  is more accurate and reliable than the 
previously 5 graded scale [Junghard,1998]. The following  symptoms were 
assessed prior and after 3 months of treatment: dyspareunia, cystalgia and 
urinary urge. 
  Patients undertook biochemical tests ( blood, urine, stool), 
bacteriological examination of urine and stools, parasitological stool exams, 
colonoscopy, abdominal and pelvic ultrasound with concurrent transvaginal 
examination, interdisciplinary consultations:  gynecological and urological 
ones, in order to rule out other conditions and causes of their symptoms.  
  Patients were randomly devised in 2 groups , each of 15 
patients.First group received gabapentin in gradually increasing amount up to 
the dose of 1200mg/day, the second group received  2x300mg/day of 
gabapentin associated with probiotics (1 billion strains/ capsule  
Lactobacillus acidophilus 50% and Bifidobacterium bifidus 50% ),3 
capsules/day plus dimeticone 80 mg, 3x2 chewing  pills/day for 3 months 
long. 
  The study was aproved by the local ethical comitee and patients  
provided written informed consent.  
 Statistical analysis  was  made using GraphPad software with the 
panel for continous data,  with calculation of mean values and standard 
deviation, unpaired t test, p values with CI= 95%. 
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Results 
 Our patients baseline clinical data, depicted in table I, showed no 
statistically significant difference between the two groups of patients. 
Tabel I Baseline clinical data 
Baseline clinical data 
 
First group 
 Second group P 
Hb(11,7-16,1g/dl) 12,19±0,43 12,29±0,40 P=0,48 
RBC(3,8- 5,2x1000,000/microL) 4,16±0,21 4,10±0,22 P=0,44 
WBC(4-10x1000/microL) 4,84±0,52 4,81±0,62 P=0,87 
CRP(<0,5/dl) 0,20±0,08 0,23±0,07 P=0,36 
ALAT(<31U/L) 24,27±4,37 23,33±3,15 P=0,50 
Creatininemia(0,5-0,9 mg/dl) 0,74±0,10 0,72±0,77 P=0,43 
Fasting blood sugar  level(60-99 mg/dl) 77,32±8,11 76,40±7,62 P=0,80 
Urine bacteriology(<1000 CFU/mL) <1000 <1000 - 
Stool exams  parasitology and 
bacteriology Negative Negative - 
 
 Legend: Hb= hemoglobin, RBC = red blood count, WBC = white 
blood count, ALAT = alanin-aminotranspherase, CRP = C reactive protein, 
CFU= colonies formating units 
 As seen in table II and figure 1, the first group that was treated with 
gabapentin alone, high dose, had a statistically significant difference of 
scoring only for dyspareunia (p=0,0022).The other two symptoms, 
respectively cystalgia and urinary urge didn’t show any statistically 
significant difference of scoring after this treatment (p=0,056 and p=0,26). 
Tabel II Therapy results in  the first group of patients 
Symptoms Prior therapy scoring After therapy scoring P 
Dyspareunia 2,93±0,88. 2,20 ±0,77 (p=0,0022) 
Cystalgia 3±1,31 2,2±0,86 (p=0,058) 
Urinary urge 2,58±1,25 2,07±0,73 (p=0,26) 
 
 
   
Figure 1. First group treated with gabapentinum alone, therapy results 
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 Results recorded from the second group of patients, those that have 
associated probiotics and dimeticone to gabapentin half dose, are depicted in 
the table III and figure 2, showing a much better outcome, with statistically 
significant difference of scoring for all the symptoms that have been 
assessed: 
Tabel III Therapy results in the second group of patients 
Symptoms Prior therapy scoring After therapy scoring p 
Dyspareunia 
 3,13±1,06 1,6±0,63 (p<0,0001) 
Cystalgia 2,73±1,16 1,40±0,50 (p=0,0003) 
Urinary urge 1,87±1,13 0,66±0,61 (p=0,0011)  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Figure 2. Results in second group treated with associated probiotics and dimeticone 
 
Discussions 
 Fighting  pain in IBS is not such an easy task due to the complexity 
of involved  pathogenic pathways.  
 It is well described that people with IBS report worse quality of life, 
compared with the general public and with those with chronic disease 
conditions, such as lung disease, heart failure and diabetes, fibromyalgia, 
chronic fatigue syndrome [Gralnek,2000].  
 While altered bowel habits and pain may be the major factors that 
affect daily functioning, lifestyle, and hence quality of life, other factors 
associated with IBS may also affect quality of life, especially in women. 
  Pelvic floor disorders, such as pelvic organ prolapse, urinary urgency 
and incontinence,[Monga 1997, Jelovsek, 2005] and sexual 
dysfunction[Guthrie 1987,Fass,1998] have been associated with IBS in 
women and can all influence overall quality of life. 
 Several studies have described that women with IBS have a higher 
likelihood of a co-diagnosis of other somatic conditions.  
 One study found that women with interstitial cystitis or painful 
bladder syndrome had a greater likelihood of an antecedent diagnosis of 
fibromyalgia, chronic fatigue syndrome and IBS.[Warren, 2009] 
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  A systematic review of the comorbidities associated with IBS 
described a high prevalence of somatic syndromes such as fibromyalgia 
(33% ),chronic pelvic pain (50%),  dysuria (50%) and interstitial cystitis 
(30%).  It is not clear whether these other diagnoses were initially 
misdiagnoses or whether these conditions coexist, but it is suggested that 
there is a subgroup of IBS patients who have these other coexisting somatic 
disorders and often have higher levels of anxiety or depression. Whether 
these disorders are related because of underlying psychological factors or a 
common pathophysiological mechanism remains unknown.[Riedl, 2008, 
Mikocka-Walus, 2008,Wang,2010]. 
 Other studies observed the relationship between bladder and bowel 
function. There is a clear statement of a “complex physiology of urologic 
and gastrointestinal function”, practically an interrelation, which “has 
implications for the management of disorders affecting both organ 
systems”.This complexity is based on the convergence of dorsal root ganglia 
neurons, “ receiving sensory input from multiple pelvic organs, that have 
been identified in the colon, bladder and reproductive organs”. It’s about a 
process of “cross-sensitization, or 'crosstalk', between neural pathways in the 
pelvic organs, necessary for the routine mediation of bladder, bowel and 
sexual function” which also mediates some functional changes in pelvic 
organs close related to dysfunctions of others located in proximity. 
Consequently, crosstalk between the bladder and bowel may play a role in 
pelvic disorders, including chronic pelvic pain syndromes and overactive 
bladder symptoms[Kaplan,2013]. In fact there is still a lot of overlap" among 
pelvic pain conditions " [Heitkemper,2005] 
 The notion of dysfunction of central nervous system may be present 
in IBS is supported by studies using both PET and functional MRI. The 
perception of acute rectal stimulation is associated with anterior cingulate 
cortex activation in controls while patients with IBS showed an aberrant 
brain activation pattern both during noxious rectal stimulation and in 
anticipation of rectal pain [Silverman,1997]. Gender-related differences in 
brain activation patterns in response to colonic distention have also been 
noted [Naliboff,2003]. 
 Taking all these neurological tribulations into account we considered 
that the treatment with gabapentin curently used for controling pain in 
various conditions including fibromyalgia seemed quite reasonable. In this 
view, with pain in IBS having many different pathways,  treatment with 
Gabapentin may interfere one or more of them[Moore,2011]. 
 The "visceral hyperalgesia" may explain the role of specific dietary 
substances in IBS symptoms, like sorbitol, fructose, and lactose intolerance, 
associated with increased gas production that may subsequently trigger 
abdominal discomfort secondary to bowel lumen distention.Therefore 
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treatment with probiotics and gas absorbent are  currently used in IBS in 
order to relief some abdominal complaints: cramps, bloating, flatulence 
[Wilhelm,2008], but there are not  consistent available data about their 
efficiency in the management of pelvic floor syndrome symptoms. 
 From currently available data we’ve found, there is no record  neither 
of another study using gabapentin alone, in CPP, nor in association with 
probiotics and dimeticone.  
 Our experience showed a consistent therapeutical response in the 
second group of patients, regarding all symptoms assessed.  
 However, we should also consider the fact that all patients that joined 
this study had only mild to moderate severity symptoms. 
 Further observation should be taken in larger cohorts of patients with  
more severe complaints. 
 
Conclusion 
 This study revealed that despite high dose, gabapentin as single 
therapy had a  significant response only in mitigating dyspareunia. 
 Gabapentin in lower doses, but associated with probiotics and 
dimeticone  resulted in a satisfactory response for all the assessed 
complaints, which were significantly alleviated. 
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